Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Study

Racial inequality in receipt of medications for opioid use disorder.

Barnett ML, Meara E, Lewinson T, et al. Racial inequality in receipt of medications for opioid use disorder. New Engl J Med. 2023;388(19):1779-1789. doi:10.1056/nejmsa2212412.

Save
Print
May 31, 2023
Barnett ML, Meara E, Lewinson T, et al. New Engl J Med. 2023;388(19):1779-1789.
View more articles from the same authors.

Best practices for treating patients with opioid use disorder (OUD) include prescribing medications to treat OUD (naltrexone, naloxone, or buprenorphine) and limiting prescriptions of high-risk medications (opioid analgesics and benzodiazepines). This study of more than 23,000 patients with an index event related to OUD sought to determine racial and ethnic differences in safe prescribing. White patients were significantly more likely to receive buprenorphine and less likely to receive high-risk medications than Black or Hispanic patients in the 180 days after the index event. This difference persisted over the four-year study period.

Save
Print
Cite
Citation

Barnett ML, Meara E, Lewinson T, et al. Racial inequality in receipt of medications for opioid use disorder. New Engl J Med. 2023;388(19):1779-1789. doi:10.1056/nejmsa2212412.